<DOC>
	<DOCNO>NCT00748202</DOCNO>
	<brief_summary>The study perform investigate subcutaneous ( s.c. ) versus intravenous ( i.v . ) administration Berinert P patient hereditary angioedema ( HAE ) establish second administration mode case i.v . access suitable . The study plan single centre , randomize , open-label , cross-over pharmacokinetic study . Subjects either start s.c. i.v . pasteurised C1-Inhibitor concentrate ( Berinert P ) switch treatment administer .</brief_summary>
	<brief_title>Berinert P Study Subcutaneous Versus Intravenous Administration</brief_title>
	<detailed_description>Patients hereditary angioedema ( HAE ) , suffer recur mostly unforeseeable attack acute oedema subcutaneous tissue various organ . The pathophysiological correlate disease deficiency functionally active C1-Esterase Inhibitor ( C1-INH ) . Today , two main type HAE describe . In HAE type I , impair synthesis elevate turnover normal functional active C1-INH molecule take place , cause reduce amount functionally active C1-INH . In HAE type II , normal level functionally impair C1-INH molecule synthesize . Both defect inherit autosomal dominant trait . HAE type III limit female associate C1-INH deficiency ; pathophysiology type remains determine . Corticosteroids , antihistamine epinephrine usually exert positive effect acute attack cause HAE . This particular importance type medication often use case oedema general . In case acute oedema patient suffer HAE , intravenous administration C1-INH concentrate ( e.g. , Berinert P ) treatment choice . The study perform investigate s.c. versus i.v . administration Berinert P patient hereditary angioedema ( HAE ) establish second administration mode case i.v . access suitable .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1s</mesh_term>
	<mesh_term>Complement C1 Inhibitor Protein</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Subjects establish diagnosis HAE type I ( C1Inhibitor activity &lt; 50 % C1Inhibitor antigen &lt; 15.4 mg/dl ) HAE type II ( C1Inhibitor activity &lt; 50 % C1Inhibitor antigen normal elevate concentration dysfunctional protein ) . Male female subject age least 18 year . Subjects provide informed consent . Subjects without establish diagnosis HAE . Last C1INH administration le 7 day ago and/or acute attack . Subjects acquire angioedema ( AAE ) . All type angioedema associate C1INH deficiency . Treatment investigational drug ( exclusive drug appropriate treatment acute angioedema ) 30 day study treatment . Treatment drug appropriate treatment acute angioedema within 7 day start study treatment phase . Danazol prophylaxis . Prophylaxis antifibrinolytics , EACA , tranexamic acid . Subjects know hypersensitivity study medication ( Berinert P ) . Pregnant woman ( pregnancy rapid assay require woman childbearing potential ) , woman currently breastfeed , intention breastfeed Subjects malignant disease . Subjects immunodeficiency establish acquire immunodeficiency syndrome . Subjects concurrent serious acute illness infection per investigator judgement . Subjects mental condition render subject legally acceptable representative unable understand nature , scope possible consequence study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Hereditary angioedema</keyword>
	<keyword>C1-Esterase inhibitor</keyword>
	<keyword>intravenous</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>pharmacokinetic</keyword>
</DOC>